On August 20, 2024, Pathalys Pharma, Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, announced it successfully closed a $105 million Series B financing round. The oversubscribed financing was led by TCGX and joined by other notable investors including JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, and JPS Growth Investment Limited Partnership, and included support from Pathalys' founding investors, Catalys Pacific and DaVita Venture Group. The funds raised via this financing will be utilized to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations. 

Wilson Sonsini Goodrich & Rosati advised JP Morgan Life Sciences Private Capital on the transaction. The Wilson Sonsini team was led by Marty Waters, Dan Koeppen, and Kassandra Castillo.

For more information, please see the press release.